Denosumab treatment beyond 12 months was linked to higher jaw necrosis risk without further reduction in skeletal events in ...

A cohort study in patients with bone-metastatic castration-resistant prostate cancer found that 7–12 months of denosumab ...

Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial Although all authors completed the disclosure declaration, the ...

Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer Denosumab products play a key role in ...

The 2 denosumab biosimilars previously received FDA approval for select patients with multiple myeloma, solid tumor bone metastases, and osteoporosis. "We are pleased to have achieved a global ...

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively. The FDA has approved 2 denosumab ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...